IO Biotech, Inc., was incorporated in Delaware on May 25, 2021. The company is a clinical-stage biopharmaceutical company developing novel, immune-modulated cancer therapies based on its T-win technology platform. The company's product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. The company believes that this represents a shift in cancer management, and the company's product candidates have the potential to become the cornerstone of a variety of solid tumor treatment options. The company's T-win platform is a new approach to cancer immunotherapy designed to activate naturally occurring T cells to drive targeted immunosuppressive mechanisms.